Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 11,341 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 11,341 shares of SiBone stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $17.43, for a total transaction of $197,673.63. Following the completion of the sale, the chief executive officer owned 408,363 shares of the company’s stock, valued at $7,117,767.09. This trade represents a 2.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Laura Francis also recently made the following trade(s):

• On Tuesday, November 18th, Laura Francis sold 5,411 shares of SiBone stock. The stock was sold at an average price of $17.70, for a total transaction of $95,774.70.
• On Tuesday, November 11th, Laura Francis sold 5,411 shares of SiBone stock. The stock was sold at an average price of $17.06, for a total value of $92,311.66.

SiBone Price Performance

Shares of NASDAQ:SIBN traded up $0.24 during trading on Wednesday, hitting $18.60. 472,223 shares of the stock were exchanged, compared to its average volume of 442,797. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The company has a market cap of $807.05 million, a PE ratio of -36.47 and a beta of 0.81. SiBone has a 12-month low of $11.70 and a 12-month high of $20.05. The company has a fifty day moving average price of $15.40 and a two-hundred day moving average price of $16.72.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $48.66 million during the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. SiBone has set its FY 2025 guidance at EPS. On average, analysts forecast that SiBone will post -0.78 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on SIBN. Truist Financial decreased their price objective on shares of SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On SiBone

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SiBone during the first quarter valued at approximately $34,000. State of Alaska Department of Revenue bought a new position in shares of SiBone in the 3rd quarter worth approximately $39,000. State of Wyoming bought a new stake in shares of SiBone during the 2nd quarter valued at $55,000. Canada Pension Plan Investment Board purchased a new stake in SiBone in the second quarter worth about $68,000. Finally, Virtus Advisers LLC bought a new position in SiBone during the 1st quarter valued at approximately $58,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.